2021
DOI: 10.1016/j.jinf.2021.01.010
|View full text |Cite
|
Sign up to set email alerts
|

Seroprevalence of antibodies against SARS-CoV-2 in a large national hospital and affiliated facility in Tokyo, Japan

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
17
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
8
1

Relationship

5
4

Authors

Journals

citations
Cited by 24 publications
(20 citation statements)
references
References 8 publications
3
17
0
Order By: Relevance
“…We confirmed that the breakthrough cases occurred independently in different timings and departments, showing no evidence of clustered infection in the hospital. This finding is consistent with our previous reports from the first and second serological surveys in NCGM before the vaccination program, 12,13 suggesting that infection among the staff had occurred mainly outside the hospital (household, community, etc.). NCGM has adopted comprehensive measures against nosocomial infection since the early phase of the epidemic.…”
Section: Discussionsupporting
confidence: 93%
“…We confirmed that the breakthrough cases occurred independently in different timings and departments, showing no evidence of clustered infection in the hospital. This finding is consistent with our previous reports from the first and second serological surveys in NCGM before the vaccination program, 12,13 suggesting that infection among the staff had occurred mainly outside the hospital (household, community, etc.). NCGM has adopted comprehensive measures against nosocomial infection since the early phase of the epidemic.…”
Section: Discussionsupporting
confidence: 93%
“…Low seroprevalence in the general population in Lao PDR, 2020 is similar to studies from other countries in southeast Asia where COVID-19 cases were low [30] and in contrast to high incidence countries [31] . Healthcare workers are particularly at risk of infection and our data showing low seroprevalence are again in agreement with studies from countries with low reported COVID-19 cases [32] , [33] , [34] , and in contrast to higher seroprevalence in countries with higher incidence of confirmed COVID-19 cases, including in East Asia [35] .…”
Section: Discussionsupporting
confidence: 92%
“…Data for the present study were obtained from the first survey in July, 2020 (after the first wave of epidemic in Japan), of the NCGM Clinical Epidemiology Study on the SARS-CoV-2 antibody, an ongoing epidemiological study involving staff members at the NCGM. 15 The objective of the study was to investigate the prevalence and determinants of SARS-CoV-2 infection. On recruitment, participants were asked to complete an electronic questionnaire on sociodemographic factors, COVID-19-related work factors, lifestyle factors, and depressive symptoms.…”
Section: Methodsmentioning
confidence: 99%